OR WAIT 15 SECS
The addition of 20,000 sq. ft. of manufacturing and office space increases Avecia’s Milford, Ma, oligonucleotide capacity to 3.0 mol.
Nitto Denko Avecia Inc. (Avecia) announced on July 13, 2017 that the company will open a new oligonucleotide API manufacturing facility in Milford, MA in August 2017. The expansion will add 20,000 sq. ft. of manufacturing and office space at the site and provide CGMP oligonucleotide manufacturing capacity up to 1.8 mol, bringing the site capacity to 3.0 mol.
The company reported that it has added more than 120 jobs in Massachusetts in the past 12 months in Milford and currently has more than 50 open positions in microbiology, analytical chemistry, manufacturing, quality assurance, and engineering at its four locations in Massachusetts, Ohio, and California.
“This expansion will help Avecia’s clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials as planned,” said Detlef Rethage, president of Avecia, in a July 13, 2017 press statement. “Avecia takes pride that our engineers have introduced novel technology, executed this expansion in record time, and in close collaboration with A/Z Corporation to ensure the timely supply of novel oligonucleotide therapeutics.”
An opening ceremony is scheduled for August 2017.
Source: Nitto Denko Avecia